Table 1.

Overview of the purified anti-CS and anti-CUB autoantibodies from 13 iTTP patients

Patient codeIDAntibody concentration (µg/mL)
Anti-CSAnti-CUB
MF-KB-TTP01-A 64 108 
MF-KB-TTP02-A 58  
MF-KB-TTP03-A  56 
MF-KB-TTP05-A  101 
MF-KB-TTP09-A 35  
MF-KB-TTP10-A 50 73* 
MF-KB-TTP11-A 114  
MF-KB-TTP12-A 124  
MF-KB-TTP13-A 75  
MF-KB-TTP15-A 30  
MF-KB-TTP17-A 51  
MF-KB-TTP18-A   
MF-KB-TTP20-A 69 214 
Patient codeIDAntibody concentration (µg/mL)
Anti-CSAnti-CUB
MF-KB-TTP01-A 64 108 
MF-KB-TTP02-A 58  
MF-KB-TTP03-A  56 
MF-KB-TTP05-A  101 
MF-KB-TTP09-A 35  
MF-KB-TTP10-A 50 73* 
MF-KB-TTP11-A 114  
MF-KB-TTP12-A 124  
MF-KB-TTP13-A 75  
MF-KB-TTP15-A 30  
MF-KB-TTP17-A 51  
MF-KB-TTP18-A   
MF-KB-TTP20-A 69 214 

Patient code, patient ID, and the antibody concentration (µg/mL) of the anti-CS or anti-CUB autoantibodies after purification using CS- or CUB-affinity chromatography, respectively. Antibody concentrations were measured via spectrophotometry at optical density 280 nm (OD280 nm). Green or purple boxes indicate that autoantibodies were eluted from the CS- or CUB-affinity column, respectively, and that they consisted of anti-CS or anti-CUB autoantibodies because they showed specific binding to CS or CUB, respectively, in ELISA (Figure 1A-B), with the exception of the anti-CUB autoantibody fraction of patient F (*), which also recognized T2-T8 (Figure 1B). This anti-CUB autoantibody fraction was not studied further. Gray boxes indicate that no autoantibody was eluted from the CS- or CUB-affinity column (Figure 1A-B).

Close Modal

or Create an Account

Close Modal
Close Modal